Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Document › Details

Evox Therapeutics Ltd.. (6/9/20). "Press Release: Evox Therapeutics Announces a Multi-target RNA Interference and Antisense Research Collaboration and License Agreement with Lilly".

Organisations Organisation Evox Therapeutics Ltd.
  Organisation 2 Eli Lilly & Co. Inc. (NYSE: LLY)
  Group Eli Lilly (Group)
Products Product DeliverEX™ exosome drug platform
  Product 2 RNAi drug (RNAi therapeutic)
Index term Index term Lilly–Evox Therapeutics: drug delivery technology, 202006– collab + license $20m upfront+ $1.2b milestones DeliverEX for RNAi /ASO for CNS diseases
Persons Person de Fougerolles, Antonin (Tony) (Evox Therapeutics 2017– CEO before Ablynx + Moderna Therapeutics + Tolerx + Alnylam)
  Person 2 Hutton, Michael (Eli Lilly 202006 VP of Neurodegeneration Research)
     


Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders


Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox’s proprietary DeliverEX™ platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders. During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies. Any resulting candidate handover and technology transfer to Lilly will occur after pre-clinical proof of concept studies have been completed.

Under the terms of the agreement, Evox will receive a $20 million cash up-front payment, research funding over three years, as well as a $10 million investment from Lilly in exchange for a convertible bond from the Company. Evox will also be eligible for potential pre-clinical and clinical development, regulatory and commercial milestones of up to approximately $1.2 billion, as well as tiered royalties up to low double digits on net sales of products arising from the collaboration.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “This agreement with Lilly allows us to explore both the potential of our platform to deliver oligonucleotide payloads, a class of drugs of increasing importance, and the suitability of our exosome technology for CNS targeting. This new deal with another major pharmaceutical company highlights the breadth of opportunity that exists with exosome-based drugs.”

“We are pleased to enter into this pre-clinical research and licensing collaboration with Evox, and look forward to studying the potential for their technology to support the development of future medicines for neurological disorders,” said Michael Hutton, Ph.D., Vice President of neurodegeneration research at Lilly.


For enquiries, please contact:

Dr Antonin de Fougerolles, Chief Executive Officer, Evox Therapeutics Ltd +44 (0) 1865 819140
Simon Conway / Natalie Garland-Collins, FTI Consulting +44 (0) 203 727 1000


About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics. Backed by Oxford Sciences Innovation and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

   
Record changed: 2021-02-21

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Evox Therapeutics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px




» top